Actively Recruiting
Patient-derived Organoids of Lung Cancer to Test Drug Response
Led by University Hospital, Geneva · Updated on 2024-06-03
50
Participants Needed
1
Research Sites
560 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
CONDITIONS
Official Title
Patient-derived Organoids of Lung Cancer to Test Drug Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically proven lung cancer
- Age 63 18
- Written informed and signed consent
- Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour
You will not qualify if you...
- Less than 18 years of age
- Not able to give informed consent (language, intellectual capacities, etc.)
- Not accessible to biopsy and/or surgery sample
- Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Geneva University Hospitals
Geneva, Switzerland, 1205
Actively Recruiting
Research Team
V
Veronique SERRE-BEINIER, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here